SCHEMBL5019609

SCHEMBL5019609

CC1=C(c2ccc(NC(=O)c3cccc(F)c3C)cc2)CN(c2nnn(C)n2)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AVPR2 P30518 1/20 0.42
KMT2A Q03164 3/20 0.41
JAK1 P23458 1/20 0.38
MAPT P10636 3/20 0.37
TP53 P04637 2/20 0.37
RAB9A P51151 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
NPC1 O15118 1/20 0.37
ALDH1A1 P00352 1/20 0.37
MCL1 Q07820 1/20 0.37
TDP1 Q9NUW8 2/20 0.37
MAPK10 P53779 2/20 0.36
MAPK14 Q16539 2/20 0.36
TNF P01375 1/20 0.36
IL2 P60568 1/20 0.36
STIM1 Q13586 1/20 0.36
ORAI1 Q96D31 1/20 0.36
CTDSP1 Q9GZU7 1/20 0.36
CHRNA7 P36544 3/20 0.36
KCNH2 Q12809 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5019638 0.93 KMT2A (0.41) AVPR2KMT2AJAK1MAPTTP53
SCHEMBL1781817 0.93 KMT2A (0.50) KMT2AJAK1MAPTTP53RAB9A
SCHEMBL5019637 0.92 KMT2A (0.41) KMT2AJAK1MAPTTP53RAB9A
SCHEMBL987243 0.90 IL2 (0.43) KMT2AJAK1MAPTTP53RAB9A
SCHEMBL4561040 0.89 KMT2A (0.35) AVPR2KMT2AMAPTRAB9ANPC1
SCHEMBL5019599 0.88 SMN1; SMN2 (0.40) KMT2ATP53RAB9ASMN1; SMN2NPC1
SCHEMBL5019598 0.88 IL2 (0.40) KMT2AJAK1RAB9ANPC1TNF
SCHEMBL5019716 0.86 RAB9A (0.47) KMT2AMAPTTP53RAB9ASMN1; SMN2
SCHEMBL1781784 0.86 SMO (0.44) KMT2AMAPTRAB9ASMN1; SMN2NPC1
SCHEMBL986998 0.85 STIM1 (0.42) KMT2ASTIM1ORAI1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012064808-A1 TETRAZOLYL - TETRAHYDROPYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE - RELATED USES SYNTA PHARMACEUTICALS CORP (US) 2012-05-18 WO disclosed